Medicus Pharma Ltd. $MDCX

By Microcap Ledger desk · CIK 0001997296

Facts as of Oct 11, 2026, 08:17 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: W. Conshohocken, PA
Fiscal year end: December 31
Shares outstanding: 63,180,610 [10-Q 2026-08-12]
as of 2026-08-10

Sources: [10-K 2026-03-25]

What the company doesAI summary of filing

Medicus Pharma Ltd. is a clinical-stage biotech company developing novel therapeutic assets through Phase 2 proof-of-concept with plans to pursue out-licensing or partnerships with established pharmaceutical companies. The company operates two main subsidiaries: SkinJect, which is developing doxorubicin-containing microneedle arrays (D-MNA) for treating non-melanoma skin cancers, particularly basal cell carcinoma, and Antev, which is developing Teverelix, a gonadotrophin-releasing hormone antagonist for advanced prostate cancer and acute urinary retention in patients with benign prostate hyperplasia. The company is pre-revenue and has no product approvals; it generates no sales revenue and advances its candidates through clinical trials. [10-K 2026-03-25]

Segments: D-MNA (doxorubicin-containing microneedle arrays), Teverelix (GnRH antagonist)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$20.66M	−$15.95M	$15.17M	[10-Q 2026-08-12]
FY ended Dec 2025	—	−$47.28M	−$22.78M	$8.71M	[10-K 2026-03-25]
FY ended Dec 2024	—	−$11.16M	−$10.25M	$4.16M	[10-K 2026-03-25]

Quarterly cash burn: −$7.98M
Cash runway Estimate: ~5.7 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2025-04-15	13,428,561	[10-K/A 2025-04-30]
2025-05-08	13,494,861	[10-Q 2025-05-12]
2025-08-11	17,816,266	[10-Q 2025-08-11]
2025-11-11	22,029,144	[10-Q 2025-11-14]
2026-03-17	39,362,109	[10-K 2026-03-25]
2026-04-15	41,818,092	[10-K/A 2026-04-29]
2026-05-07	56,658,164	[10-Q 2026-05-14]
2026-08-10	63,180,610	[10-Q 2026-08-12]

Shelf registration: S-3 filed 2026-01-30; declared effective 2026-02-04 [S-3 2026-01-30]

Listing status

Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-27. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-05-27	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-05-27]
2026-04-24	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-04-24]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-09-04	Smith Andrew Alasdair	grant	735,294	$0.17	[4 2026-09-08]
2026-09-04	Mehmud Faisal	grant	1,470,588	$0.17	[4 2026-09-08]
2026-09-04	Brennan Edward J.	grant	588,235	$0.17	[4 2026-09-08]
2026-09-04	Bonner Carolyn F.	grant	1,470,588	$0.17	[4 2026-09-08]
2026-09-04	Bokhari Raza	grant	2,941,176	$0.17	[4 2026-09-08]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-07	424B3	Prospectus or prospectus supplement
2026-10-07	8-K	Other events
2026-09-14	13D	Beneficial ownership report (5%+ holder)
2026-09-14	424B3	Prospectus or prospectus supplement
2026-09-14	8-K	Material agreement terminated
2026-09-11	8-K	Unregistered sale of equity
2026-09-03	424B3	Prospectus or prospectus supplement
2026-09-03	8-K	Material agreement entered
2026-08-13	424B3	Prospectus or prospectus supplement
2026-08-12	10-Q	Quarterly report
2026-06-04	424B3	Prospectus or prospectus supplement
2026-06-04	8-K	Shareholder vote results

Facts as of Oct 11, 2026, 08:17 AM UTC. Small caps move fast; check the latest filings.